# US 2021/0277082 A1 · Methods and compositions for increasing red blood cells > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0277082 A1 - Document ID: US20210277082A1 - Status: Published application - Kind: A1 - Application number: 17/063,848 - Filed: 2020-10-06 - Published: 2021-09-09 - Earliest claimed: 2012-04-06 - Assignees: Acceleron Pharma Inc. - Applicants: Acceleron Pharma Inc. - Inventors: Ravindra Kumar; Naga Venkata Sai Rajasekhar Suragani; John Knopf - Web page: https://patentgrep.com/patent/US20210277082A1 ## CPC - C07K 14/51: Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor - A61P 7/06: Antianaemics - C07K 2319/02: containing a signal sequence - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. ## Claims ### Claim 1 A method for increasing red blood cell levels or treating anemia associated with thalassemia in a patient, the method comprising administering to a patient in need thereof a polypeptide selected from the group consisting of a BMP9 polypeptide and a BMP10 polypeptide. ### Claim 2 (depends on 1) The method of claim 1, wherein the polypeptide is a BMP9 polypeptide. ### Claim 3 (depends on 2) The method of claim 2, wherein the BMP9 polypeptide comprises an amino acid sequence that is at least 63% identical to the sequence of SEQ ID NO.: 3. ### Claim 4 (depends on 2) The method of claim 2, wherein the BMP9 polypeptide comprises an amino acid sequence that is encoded by a nucleic acid that hybridizes under stringent hybridization conditions to the a nucleic acid that is complementary to the sequence of nucleotides 1121-1450 of SEQ ID NO.: 11. ### Claim 5 (depends on 2) The method of claim 2, wherein the BMP9 polypeptide comprises an amino acid sequence that is identical to the sequence of SEQ ID NO.: 3. ### Claim 6 (depends on 1) The method of claim 1, wherein the polypeptide is a BMP10 polypeptide. ### Claim 7 (depends on 6) The method of claim 6, wherein the BMP10 polypeptide comprises an amino acid sequence that is at least 63% identical to the sequence of SEQ ID NO.: 6. ### Claim 8 (depends on 6) The method of claim 6, wherein the BMP10 polypeptide comprises an amino acid sequence that is encoded by a nucleic acid that hybridizes under stringent hybridization conditions to the a nucleic acid that is complementary to the sequence of nucleotides 1108-1431 of SEQ ID NO.: 12. ### Claim 9 (depends on 6) The method of claim 6, wherein the BMP10 polypeptide comprises an amino acid sequence that is identical to the sequence of SEQ ID NO.: 6. ### Claim 10 (depends on 1) The method of claim 1, wherein the BMP9 polypeptide or BMP10 polypeptide is administered in a pharmaceutical preparation. ### Claim 11 (depends on 10) The method of claim 10, wherein the pharmaceutical preparation comprises a prodomain polypeptide selected from the group consisting of a BMP9 prodomain polypeptide and a BMP10 prodomain polypeptide. ### Claim 12 (depends on 11) The method of claim 11, wherein the prodomain polypeptide is a BMP9 prodomain polypeptide. ### Claim 13 (depends on 12) The method of claim 12, wherein the prodomain polypeptide comprises an amino acid sequence that is at least 80% identical to the sequence of amino acids 23-319 of SEQ ID NO.: 1. ### Claim 14 (depends on 12) The method of claim 12, wherein the prodomain polypeptide comprises the amino acid sequence of amino acids 23-319 of SEQ ID NO.: 1. ### Claim 15 (depends on 12) The method of claim 12, wherein the pharmaceutical preparation comprises a BMP9 polypeptide noncovalently associated with the BMP9 prodomain polypeptide. ### Claim 16 (depends on 12) The method of claim 12, wherein the pharmaceutical preparation comprises a BMP10 polypeptide noncovalently associated with the BMP9 prodomain polypeptide. ### Claim 17 (depends on 11) The method of claim 11, wherein the prodomain polypeptide is a BMP10 prodomain polypeptide. ### Claim 18 (depends on 17) The method of claim 17, wherein the prodomain polypeptide comprises an amino acid sequence that is at least 80% identical to the sequence of amino acids 22-316 of SEQ ID NO.: 4. ### Claim 19 (depends on 17) The method of claim 17, wherein the prodomain polypeptide comprises the amino acid sequence of amino acids 22-316 of SEQ ID NO.: 4. ### Claim at position 20 20-39. (canceled)